Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.57 |
| ▸ | PDE4A | P27815 | 9/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28376693 | 1.00 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL28372157 | 1.00 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL497697 | 0.95 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL497696 | 0.95 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL498305 | 0.95 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL28373126 | 0.92 | ALDH1A1 (0.58) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL25190677 | 0.89 | ALDH1A1 (0.62) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL30287170 | 0.89 | ALDH1A1 (0.62) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL7361245 | 0.86 | ALDH1A1 (0.58) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL13522989 | 0.84 | ALDH1A1 (0.68) | PDE4BALDH1A1TSHRFDPSTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981876-B | 8-substituted styrylxanthine derivatives and uses thereof | 广东东阳光药业有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-110981876-A | 8-substituted styrylxanthine derivatives and uses thereof | 广东东阳光药业有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20110021487-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021487-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021487-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2242741-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009100827-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009100827-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021487-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE | PC, DPP4, FABP3 | PDE4D 707/4885PDE4B 680/4885PDE4A 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.